The document lists several chemotherapy regimens for treating stage IV non-squamous non-small cell lung cancer without mutations in EGFR, ALK or ROS1. It provides median overall survival rates for each regimen ranging from 7.7 to 15.7 months. It notes that regimens containing pembrolizumab in combination with chemotherapy have closer to a 70% rate of patients living more than one year, compared to standard chemotherapy where around 50% of patients live about one year.

3. 18%
9%

28. NCCN Version 6.2018
Stage IV NSCLC
Non-squamous
No mutations EGFR/ALK/ROS1
PS 0-1
Systemic therapy
Bevacizumab/carboplatin/paclitaxel
Bevacizumab/carboplatin/pemetrexed
Bevcizumab/cisplatin/pemetrexed
Carboplatin/albumin-bound paclitaxel
Carboplatin/docetaxel
Carboplatin/etoposide
Carboplatin/Gemcitabine
Carboplatin/paclitaxel
Carboplatin/pemetrexed
Cisplatin/etoposide
Cisplatin/gemcitabine
Cisplatin/paclitaxel
Cisplatin/pemetrexed
Gemcitabine/docetaxel
Gemcitabine/vinorelbine
Pembrolizumab/carboplatin/pemetrexed
Pembrolizumab/cisplatin/pemetrexed
Atezolizumab/carboplatin/paclitaxel/bevacizumab

29. PCB pCB pcB CNa CDo CE CG PC pC cDo cE cG cP cp GDo GVi 189 c189
PCB 12.3 13.4
pCB 12.6
pcB 15.7
CNa 12.1
CDo 9.4
CE 11
CG 7.7
PC 10.3 11.1 12.3 9.0 7.9
pC 10.5 49%
cDo 11.3 11.3
cE 7.6 7.2 7.9
cG 14.1 8.7 7.9 10.9
cP 7.9
cp 12.6 49%
GDo 11.1
GVi 11.5
189 69%
c189 69%

30. PCB pCB pcB CNa CDo CE CG PC pC cDo cE cG cP cp GDo GVi 189 c189
PCB 12.3 13.4
pCB 12.6
pcB 15.7
CNa 12.1
CDo 9.4
CE 11
CG 7.7
PC 10.3 11.1 12.3 9.0 7.9
pC 10.5 49%
cDo 11.3 11.3
cE 7.6 7.2 7.9
cG 14.1 8.7 7.9 10.9
cP 7.9
cp 12.6 49%
GDo 11.1
GVi 11.5
189 69%
c189 69%

31. PCB pCB pcB CNa CDo CE CG PC pC cDo cE cG cP cp GDo GVi 189 c189
PCB 12.3 13.4
pCB 12.6
pcB 15.7
CNa 12.1
CDo 9.4
CE 11
CG 7.7
PC 10.3 11.1 12.3 9.0 7.9
pC 10.5 49%
cDo 11.3 11.3
cE 7.6 7.2 7.9
cG 14.1 8.7 7.9 10.9
cP 7.9
cp 12.6 49%
GDo 11.1
GVi 11.5
189 69%
c189 69%
50% live about 1 year
Close to 70% live more than 1 year
with Pembro + Chemo

32. Thank you!